SEINE BIO · PEPTIDE PROFILE
Liraglutide
GLP-1 medicine · Saxenda and product-specific indications
Approved productsGet to know the name, understand the evidence, and prepare a more informed conversation.
What is Liraglutide?
Saxenda is an approved GLP-1 medicine for defined weight-management populations, alongside diet and physical activity. Medical eligibility and product-specific warnings matter. Source & further reading.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Liraglutide.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
Liraglutide is a GLP-1 receptor agonist with a longer clinical history than the newer weekly weight-care medicines. Saxenda and Victoza contain the same active molecule but serve different labeled prescribing purposes. A useful comparison starts with the actual product, indication and daily treatment requirements rather than treating every GLP-1 medicine as interchangeable.
Community Use
Peptidepedia’s liraglutide profile discusses weight management and comparisons with semaglutide. This reflects a publisher’s framing, not proof that one option is best for you. No molecule-specific PeptideDosages protocol was verified here. The clinical reference is the finished prescription product and its evidence, not a generic community cycle.
Doses, Durations & Cycles
Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous injection | Initial: 0.6 mg daily for 1 week 3 mg daily in adults; lower adult doses are for escalation. | Once daily | Long-term weight management. Adult response is reassessed 16 weeks after initiation; discontinue if weight loss is less than 4% of baseline. Break: No informal off-cycle established by this source | FDA prescribing information Saxenda FDA prescribing information, section 2.3 (DailyMed) |
Important context: The injection is daily. The label's weekly escalation steps do not mean weekly administration or a fixed 16-week treatment cycle.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The Saxenda label describes gradual escalation toward a daily adult maintenance target. That maintenance amount is not a first-day dose. The separate table preserves label context. Suitability, tolerability and continuation decisions belong to the treating clinician, including what to do after interruption rather than restarting from a community chart.
Research Findings
The 2015 SCALE trial compared liraglutide with placebo over 56 weeks alongside diet and exercise support. The study examined weight change in adults with overweight or obesity. Its year-long context is a useful correction to advertisements that suggest a medicine produces a predictable transformation within a few days.
U.S. Approval & Access
FDA-approved liraglutide products exist for specific diabetes and weight-care uses. Saxenda’s authorization does not validate an unofficial vial, a different formulation or a recreational body-composition program. Confirm the exact medicine and indication with the prescriber and dispensing pharmacy. Approval also does not mean every patient meets the product’s clinical criteria. DailyMed’s product record lists DEA Schedule: None. Prescription and lawful-dispensing requirements still apply; being unscheduled does not authorize research-material sale for patient use.
What It Does in the Body
Liraglutide activates GLP-1 receptors involved in appetite and glucose physiology. The daily formulation is one practical distinction from some later medicines. Biological similarity does not erase differences in exposure, studies or tolerability. The most useful discussion compares the actual care experience you can sustain, not simply whether a product is newer. Its label describes an approximately 13-hour elimination half-life. Drug exposure is not a prediction of the onset, peak or lasting duration of someone’s weight response.
Benefits & Reported Experiences
The SCALE study reported mean weight losses of 8.4 kg with liraglutide and 2.8 kg with placebo at 56 weeks. Those averages are specific to that trial and analysis. Individual results vary. Ask how your clinician will assess benefit and when treatment should be reconsidered if progress or tolerability is inadequate.
Side Effects & Risks
Common digestive effects and serious label precautions need review. The thyroid-tumor contraindications, pancreatitis and gallbladder warnings are not replaced by reassurance that liraglutide has been used for years. Tell the prescriber about pregnancy plans, severe digestive symptoms and other glucose-lowering medicines. An older medicine still requires an individualized risk discussion.
Delivery Options
Saxenda is a finished prescription injection with its own administration instructions. Daily use should not be reconstructed from the instructions for a weekly GLP-1 medicine. This guide does not teach vial preparation or injection technique. If you are prescribed it, the pharmacist and clinical team should provide product-specific education and clarify interruptions or missed treatment.
Product Quality & Storage
Look beyond the advertised monthly price. Confirm the brand or approved generic, device, supplied quantity, dispensing source and follow-up arrangements. Changing between products can change the instructions even when the active molecule is familiar. Keep the prescription and packaging together when asking the pharmacy to resolve a discrepancy. Saxenda’s label specifies refrigeration at 2–8°C before first use; an in-use pen has a 30-day limit under its permitted conditions. Do not freeze it, and protect it from heat and light.
Combinations & Interactions
The Saxenda label advises against coadministration with another liraglutide product or GLP-1 receptor agonist. Its weight-care evidence does not establish every combination with other weight-loss products. Give the clinician a complete list rather than separating prescription medicines from supplements and research substances as though they could not interact.
Talking With Your Provider
Discuss whether daily treatment fits your routine, which health outcomes matter and what a reassessment plan should include. Liraglutide may be one possible clinical option, but comparison is more useful than chasing a particular name. A care conversation can also identify an alternative medicine or non-medication approach when appropriate.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →